Crossmark

Development of a new micellar formulation of carvedilol and curcumin to enhance blood pressure reduction in a spontaneously hypertensive rat model

Published Online: 2024-10-18

Published Print: 2025-04

Authors

Santander Plantamura, Yanina Alejandra

Allo, Miguel

Riedel, Jennifer

Fuentes, Pedro

Riesco, Ana Sol

Bernabeu, Ezequiel

Garcés, Mariana

Evelson, Pablo

Gorzalczany, Susana

Carranza, Andrea

Höcht, Christian

Chiappetta, Diego
Funding

Funding for this research was provided by:

Universidad de Buenos Aires, Argentina (UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA, UBACYT 200201301-00547BA)
License Information

Text and Data Mining valid from 2024-10-18

Version of Record valid from 2024-10-18
More Information

Article History

Received: 21 August 2024

Accepted: 9 October 2024

First Online: 18 October 2024

Declarations

:

: All applicable international laws for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution where the studies were conducted. All experiments were carried out according to the guidelines of the Animal Use and Care Committee of the Faculty of Pharmacy and Biochemistry, University of Buenos Aires (CICUAL-FFyB) (EXP-UBA: 0037832/19, resolution no. 2194/19).

: The authors declare no competing interests.

Document is current